All In Biotech

Drug Trial Radar · NCT06323356

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

18

Actual

Start

Mar 19, 2024

Primary completion

Oct 17, 2025

Study completion Jul 10, 2026

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Mar 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

Conditions

  • Generalized Pustular Psoriasis
  • Erythrodermic Psoriasis

Interventions

  • TAK-279Drug

    Specified drug on specified days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater Than or Equal to (>=) 2-Point Decrease From Baseline at Week 16Time frame: At Week 16
  2. Percentage of Participants Who Achieved >=75 Percent (%) Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 16Time frame: At Week 16

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Fukuoka University Hospital

    Fukuoka, Japan

  • University Hospital, Kyoto Prefectural University of Medicine

    Kyoto, Japan

  • Okayama University Hospital

    Okayama, Japan

  • Nippon Life Hospital

    Osaka, Japan

  • Osaka Metropolitan University Hospital

    Osaka, Japan

  • Nagoya City University Hospital

    Nagoya, Aichi-ken, Japan

  • Fujita Health University Hospital

    Toyoake, Aichi-ken, Japan

  • Kimitsu Chuo Hospital

    Kisarazu, Chiba, Japan

  • Juntendo University Urayasu Hospital

    Urayasu, Chiba, Japan

  • Hospital of the University of Occupational and Environmental Health, Japan

    Kitakyushu, Fukuoka, Japan

  • Isesaki Municipal Hospital

    Isesaki, Gunma, Japan

  • Kobe University Hospital

    Kobe, Hyōgo, Japan

  • Tokai University Hospital

    Isehara, Kanagawa, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • Kansai Medical University Hospital

    Hirakata, Osaka, Japan

  • Saitama Medical University Hospital

    Iruma, Saitama, Japan

  • St.Luke's International Hospital

    Chūō, Tokyo, Japan

  • The Jikei University Hospital

    Minato-ku, Tokyo, Japan

  • Tokyo Medical University Hospital

    Shinjuku-ku, Tokyo, Japan

  • Teikyo University Hospital

    tabashi City, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.